| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H48O6 |
| Molecular Weight | 468.6664 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC2(CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(=O)OC(C)C)OCCO2
InChI
InChIKey=FCDDMESBMCWDJP-PEEJLGBMSA-N
InChI=1S/C27H48O6/c1-4-5-6-9-12-16-27(31-18-19-32-27)17-15-23-22(24(28)20-25(23)29)13-10-7-8-11-14-26(30)33-21(2)3/h7,10,21-25,28-29H,4-6,8-9,11-20H2,1-3H3/b10-7+/t22-,23-,24+,25-/m1/s1
| Molecular Formula | C27H48O6 |
| Molecular Weight | 468.6664 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Mallinckrodt (previously Sucampo Pharmaceuticals) is developing nobiprostolan (RK 023), a topical therapy for male pattern baldness (androgenetic alopecia) and hypotrichosis. The drug is a physiologically active fatty acid derivative. Nobiprostolan is in Phase IIa clinical trials for the treatment of male pattern baldness.
Originator
Approval Year
|
|
ACTIVE MOIETY |
Phase IIa clinical trials for the treatment of male pattern baldness.
|
Showing 1 to 1 of 1 entries